Caas Capital Management LP Erasca, Inc. Transaction History

Caas Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $2.97 Million - $6.55 Million	764,384 New	764,384 $3.29 Million
Q4 2021 Feb 14, 2022	SELL	$12.51 - $22.75 $375,300 - $682,500	-30,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.43 - $24.34 $522,900 - $730,200	30,000 New	30,000 $637,000

117

74.3M

7.1K

40.1K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $287M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.